Opinion|Videos|June 5, 2025
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
Panelists discuss how tarlatamab’s toxicity profile differs from traditional cytotoxic therapies, highlighting its immune-related adverse effects such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, while noting its lower risk of myelosuppression and long-term organ damage compared with chemotherapy, which tends to cause cumulative toxicities such as bone marrow suppression.
Advertisement
Episodes in this series
Summary for Physicians:
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
- Tarlatamab (immunotherapy):
- Immune-related toxicities: Includes cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, and immune-related adverse events (eg, rash, colitis)
- Less myelosuppression compared with traditional chemotherapy
- Onset of adverse effects is typically within 24 to 48 hours post infusion
- Traditional cytotoxic therapies:
- Common toxicities: Myelosuppression, nausea/vomiting, alopecia, fatigue, and mucositis
- Delayed onset of adverse effects (often seen after several cycles)
- Dose-limiting toxicities often related to bone marrow suppression
Key Differences:
- Tarlatamab may cause acute immune reactions but spares long-term organ damage compared with cytotoxic therapies.
Traditional chemotherapies are associated with cumulative toxicities over time, particularly myelosuppression, which is less of a concern with tarlatamab.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5